18
Nov
2019
Feeding Frenzy: The Ecosystem is Growing Stronger
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Nov
2019
Merck’s Ebola Vaccine Triumph, Weill’s $106M Neurohub & Teva’s Reversal
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Nov
2019
Scientist, Entrepreneur, Rock Collector: Tim Springer on The Long Run
Today’s guest on The Long Run is Tim Springer. Tim wears many hats. First and foremost, he’s a scientist. An immunologist to be specific, at Harvard Medical School. He’s best known for his discovery of integrins, a class of transmembrane receptors. Now in his early 70s, Tim recently won the Gairdner Award, sometimes called the Canadian Nobel. The prize committee... Read More
12
Nov
2019
Don’t Pull Back on Basic Biology for Psychiatry: It’s Time to Double Down
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Nov
2019
Disruption, Fast and Slow
Chris Gibson, the CEO and co-founder of Recursion Pharmaceuticals, may have captured the essence of the difference in mindset between tech VCs and life science VCs, writing in a superb recent article (a response to my previous TR post): “The most consistent thread that differentiates tech and life science VCs is their willingness to project new data onto an industry and imagine resultant... Read More
7
Nov
2019
Takeda’s Busy Week, Halozyme’s Stumble, and New FDA Commish On Deck
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Nov
2019
Tech VCs and Biotech VCs: Talking Past Each Other on AI Drug Discovery
[Editor’s Note: this is a new column called “Astounding HealthTech” by TR contributor David Shaywitz.] If you want to know the difference between tech venture capitalists and biotech VCs, look at their respective views on AI applications for drug discovery. Many of the most prominent AI drug discovery startups boast exceptionally rich valuations, driven by the enthusiastic participation of tech... Read More
4
Nov
2019
New Gene-Editing Candidates Target Blood Disorders, as Gene Therapies Start to Hit the Market
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Oct
2019
Amgen’s Bet on BeiGene, David Hung’s Megaround, & Zolgensma Speed Bump
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Oct
2019
The Story of Henri Termeer: John Hawkins and Jim Geraghty on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Oct
2019
Early Cancer Screening is Maturing. What Will It Mean for Drug Developers?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Oct
2019
Vertex’s Watershed for CF, Biogen’s Head-Scratcher, and Seattle Genetics Nails HER2Climb
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Oct
2019
Biotech’s film making exec behind ‘Jim Allison: Breakthrough’
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Oct
2019
Reata Booms, Alexion Buys Achillion, & Teva Drops the Ball (Big Time)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Oct
2019
Turning Synthetic Biology Into ‘Living Drugs’: Synlogic’s Aoife Brennan on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Oct
2019
UCB’s $2B Bet on Rare Disease, BioNTech’s IPO Haircut, & Greenwood Eases Out the Door
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Oct
2019
12 VCs Who Matter, But You Hardly Ever Read About
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Oct
2019
Join Me and a Biotech Team on the Trek of a Lifetime for Cancer Research
Earlier this year, I led a team of 27 biotech professionals to Mt. Kilimanjaro, the highest peak in Africa. Each of us committed to raise $50,000 for cancer research at Fred Hutch. We ended up raising $1.6 million. We had an amazing time together. We all made it to the top. I want to do it again. This time we’re... Read More
3
Oct
2019
ESMO Wrap, A Twitchy IPO Market, & Novartis Picks Microsoft for AI Help
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
1
Oct
2019
From Farm Field to MIT Lab: Phil Sharp on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.